Condition: Bladder Cancer · Muscle Invasive Bladder Cancer (MIBC) · Muscle Invasive Bladder Cancer Urothelial Carcinoma · Sponsor: Johns Hopkins University
Radical cystectomy is the standard of care for muscle invasive bladder cancer, however despite advances, it is still associated with high morbidity. Many complications may be driven by dehydration and it is unclear if a home intravenous fluid (IVF) infusion program post-operatively, which is an accepted standard practice, is beneficial. This study is a single institution randomized controlled trial where patients who choose to undergo radical cystectomy for bladder cancer will be randomized to an Enhanced Recovery After Surgery (ERAS) protocol with a home IVF program, consisting of 1 liter (L) of crystalloid fluid three times per week for four weeks, or ERAS protocol alone. The primary outcome will be 90-day hospital re-admissions, with secondary outcomes including 30 and 90 day complications.
This description comes directly from the study's public registry record.
Tyler S Garman, MD · 410-955-6100 · tgarman1@jhu.edu
Max R Kates, MD · 410-614-0009 · Mkates@jhmi.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins Hospital | Baltimore, Maryland, United States | Not Yet Recruiting |
| Johns Hopkins Hospital | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07225205